Literature DB >> 22910836

Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention.

Bryce D Smith1, Rebecca L Morgan, Geoff A Beckett, Yngve Falck-Ytter, Deborah Holtzman, John W Ward.   

Abstract

DESCRIPTION: The Centers for Disease Control and Prevention (CDC) and a group of governmental and private sector partners developed these evidence-based recommendations to increase the proportion of hepatitis C virus (HCV)-infected persons who know their status and are linked to appropriate care and treatment. The recommendations also address brief alcohol screening, as alcohol accelerates progression of liver disease among HCV-infected individuals. These recommendations augment CDC's 1998 and 1999 recommendations based on risk and medical indications and are not meant to replace those recommendations.
METHODS: These recommendations are based on systematic reviews of evidence published from 1995 through February 2012 in MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials, Sociological Abstracts, and Database of Abstracts of Reviews of Effects. Selected studies included cross-sectional and cohort studies that addressed either prevalence of hepatitis C in the United States or clinical outcomes (for example, hepatocellular carcinoma and serious adverse events) among treated patients and systematic reviews of trials that assessed effectiveness of brief screening interventions for alcohol consumption. The Grading of Recommendations Assessment, Development, and Evaluation framework was used to assess quality of the evidence. RECOMMENDATION 1: Adults born during 1945-1965 should receive 1-time testing for HCV without prior ascertainment of HCV risk. (Grade: strong recommendation; moderate-quality evidence). RECOMMENDATION 2: All persons with identified HCV infection should receive a brief alcohol screening and intervention as clinically indicated, followed by referral to appropriate care and treatment services for HCV infection and related conditions (Grade: strong recommendation; moderate-quality evidence).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22910836      PMCID: PMC5777166          DOI: 10.7326/0003-4819-157-9-201211060-00529

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  37 in total

1.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-08-20

2.  Screening for hepatitis C virus infection in adults: recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2004-03-16       Impact factor: 25.391

3.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

4.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Authors:  Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

Review 5.  Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment.

Authors:  Brennan M R Spiegel; Zobair M Younossi; Ron D Hays; Dennis Revicki; Sean Robbins; Fasiha Kanwal
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

6.  Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States.

Authors:  David B Rein; John S Wittenborn; Cindy M Weinbaum; Miriam Sabin; Bryce D Smith; Sarah B Lesesne
Journal:  Dig Liver Dis       Date:  2010-06-17       Impact factor: 4.088

7.  Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection.

Authors:  Johan Westin; L M Lagging; F Spak; N Aires; E Svensson; M Lindh; A P Dhillon; G Norkrans; R Wejstål
Journal:  J Viral Hepat       Date:  2002-05       Impact factor: 3.728

8.  Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases.

Authors:  Rodrigo Zapata
Journal:  Ann Hepatol       Date:  2010       Impact factor: 2.400

9.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

10.  Family physicians' knowledge and screening of chronic hepatitis and liver cancer.

Authors:  Jeanne M Ferrante; Dock G Winston; Ping-Hsin Chen; Andrew N de la Torre
Journal:  Fam Med       Date:  2008-05       Impact factor: 1.756

View more
  96 in total

Review 1.  CROI 2016: Viral Hepatitis and Liver Fibrosis.

Authors:  Anne F Luetkemeyer; David L Wyles
Journal:  Top Antivir Med       Date:  2016 May-Jun

2.  The Association of Abnormal Liver Tests with Hepatitis C Testing in Primary Care.

Authors:  Andrew D Schreiner; John Bian; Jingwen Zhang; Z Merle Haulsee; Justin Marsden; Valerie Durkalski-Mauldin; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Am J Med       Date:  2019-07-29       Impact factor: 4.965

3.  High-Yield Birth-Cohort Hepatitis C Virus Screening and Linkage to Care Among Underserved African Americans, Atlanta, Georgia, 2012-2013.

Authors:  Lesley S Miller; Francois Rollin; Shelly-Ann Fluker; Kristina L Lundberg; Brandi Park; Kristi Quairoli; Nyiramugisha K Niyibizi; Anne C Spaulding
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

4.  The Cost of Hepatitis C Testing Strategies in Primary Care Patients with Abnormal Transaminases.

Authors:  Andrew D Schreiner; Don C Rockey; William P Moran
Journal:  J Gen Intern Med       Date:  2020-04       Impact factor: 5.128

5.  Optimizing the Timing of HIV Screening as Part of Routine Medical Care.

Authors:  Matthew R Golden; James P Hughes; Julia C Dombrowski
Journal:  AIDS Patient Care STDS       Date:  2017-01       Impact factor: 5.078

6.  Global Elimination of Hepatitis C Virus.

Authors:  John W Ward
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

Review 7.  Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis.

Authors:  Siddharth Singh; Antonio Facciorusso; Rohit Loomba; Yngve T Falck-Ytter
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-04       Impact factor: 11.382

8.  Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia.

Authors:  Rohit Pai; Alnoor Ramji; Samuel S Lee; Winnie W Wong; Eric M Yoshida
Journal:  Can J Gastroenterol Hepatol       Date:  2013-11-08

Review 9.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

10.  Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.

Authors:  John P Donnelly; Ricardo A Franco; Henry E Wang; James W Galbraith
Journal:  Clin Infect Dis       Date:  2015-11-26       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.